London stocks

Looking for new leadership

OXFORD - Product disappointments dominated the British biotech scene during the first quarter, which leaves investors looking for new sources of market leadership to pull the sector out of its lengthening slump.

Scotia (LSE:SOH, Stirling, U.K.) decided to dump its Amelorad diabetic neuropathy drug when it emerged that the regulators at the European Medicines Evaluation Agency would require more data before they could make a decision on the compound.